Therapeutic targeting of immunometabolism in Alzheimers disease reveals a critical reliance on Hexokinase 2 dosage on microglial activation and disease progression.

Supporters

Support the authors with ResearchCoin

Tip RSC

Preprint Server

Topics

Biology

Neuroscience

Medicine

Biochemistry

Immunology

Show all topics

DOI

10.1101/2023.11.11.566270

License

CC-BY-NC-ND

Other Formats

PDF